|(S)-(2R,3R,11bR)-3-丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯|CsnPharm

CAS No.: 1025504-45-3

Valbenazine Catalog No. CSN13715

Synonyms: NBI-98854;MT-5199;Ingrezza

Valbenazine is a prodrug of the(+)-α isomer of tetrabenazine for tardive syndrome therapy, and inhibits VMAT2 function.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Valbenazine is a prodrug of the(+)-α isomer of tetrabenazine for tardive syndrome therapy, and inhibits VMAT2 function.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02679079	Tourette Syndrome	Phase 2	Completed	-	-
NCT02879578	Tourette Syndrome	Phase 2	Completed	-	United States, Arizona ... more >> Sun City, Arizona, United States United States, California San Diego, California, United States United States, Florida Loxahatchee Groves, Florida, United States Saint Petersburg, Florida, United States Tampa, Florida, United States United States, Illinois Naperville, Illinois, United States United States, Nebraska Lincoln, Nebraska, United States United States, New Jersey Summit, New Jersey, United States United States, New York New York, New York, United States United States, Pennsylvania Norristown, Pennsylvania, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Fort Worth, Texas, United States United States, Washington Spokane, Washington, United States Collapse <<
NCT02581865	Tourette Syndrome	Phase 2	Completed	-	-

更多
参考文献

[1] Factor SA, Remington G, et al. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017 Nov 14. pii: 17m11777.
[2] Muller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015 Jun;24(6):737-42.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.3891 mL
- 11.9454 mL
- 23.8909 mL
- 5 mM
- 0.4778 mL
- 2.3891 mL
- 4.7782 mL
- 10 mM
- 0.2389 mL
- 1.1945 mL
- 2.3891 mL

技术信息

CAS号

1025504-45-3

储存条件

粉末: Keep in dark place,Sealed in dry,Store in freezer, under -20°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C24H38N2O4

运输

蓝冰

分子量

418.57

别名

NBI-98854;MT-5199;Ingrezza

溶解度

DMSO	80.0 mg/mL (191.1 mM)
Water	insoluble

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02679079	Tourette Syndrome	Phase 2	Completed	-	-
NCT02879578	Tourette Syndrome	Phase 2	Completed	-	United States, Arizona ... more >> Sun City, Arizona, United States United States, California San Diego, California, United States United States, Florida Loxahatchee Groves, Florida, United States Saint Petersburg, Florida, United States Tampa, Florida, United States United States, Illinois Naperville, Illinois, United States United States, Nebraska Lincoln, Nebraska, United States United States, New Jersey Summit, New Jersey, United States United States, New York New York, New York, United States United States, Pennsylvania Norristown, Pennsylvania, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Fort Worth, Texas, United States United States, Washington Spokane, Washington, United States Collapse <<
NCT02581865	Tourette Syndrome	Phase 2	Completed	-	-
NCT02256475	Tourette Syndrome	Phase 1	Completed	-	United States, California ... more >> San Diego, California, United States United States, Florida Kissimmee, Florida, United States St. Petersburg, Florida, United States United States, Illinois Naperville, Illinois, United States United States, Missouri St. Louis, Missouri, United States United States, Nebraska Lincoln, Nebraska, United States United States, New York New York, New York, United States Rochester, New York, United States United States, Virginia Petersburg, Virginia, United States United States, Washington Kirkland, Washington, United States Collapse <<
NCT01393600	Tardive Dyskinesia	Phase 2	Completed	-	United States, Arkansas ... more >> Woodland International Research Group, Inc Little Rock, Arkansas, United States, 72211 United States, California Synergy Clinical Research National City, California, United States, 91950 UCSD Outpatient Psychiatry San Diego, California, United States, 92103 PCSD - Feighner Research San Diego, California, United States, 92108 United States, Florida San Marcus Research Clinic, Inc. Miami, Florida, United States, 33015 Medical Research Marseilles Miami, Florida, United States, 33155 Scientific Clinical Research, Inc. North Miami, Florida, United States, 33161 United States, Georgia Atlanta Center for Medical Research Atlanta, Georgia, United States, 30308 United States, Missouri St. Louis Clinical Trials Saint Louis, Missouri, United States, 63118 United States, Texas Clinical Trials of Texas, Inc. San Antonio, Texas, United States, 78229 United States, West Virginia CAMC Clinical Trials Center Charleston, West Virginia, United States, 25304 Collapse <<
NCT01733121	Tardive Dyskinesia	Phase 2	Completed	-	United States, California ... more >> Costa Mesa, California, United States, 92626 Fountain Valley, California, United States, 92708 Oceanside, California, United States, 92056 United States, Colorado Englewood, Colorado, United States, 80113 United States, Florida Boca Raton, Florida, United States, 33486 Hialeah, Florida, United States, 33012 Miami, Florida, United States, 33125 United States, Illinois Chicago, Illinois, United States, 60640 United States, Maryland Baltimore, Maryland, United States, 21287 United States, Michigan Farmington Hills, Michigan, United States, 48334 United States, Ohio Beachwood, Ohio, United States, 44122 Middleburg Heights, Ohio, United States, 44130 United States, Pennsylvania Conshohocken, Pennsylvania, United States, 19428 Phoenixville, Pennsylvania, United States, 19460 United States, Texas Bedford, Texas, United States, 76021 DeSoto, Texas, United States, 75115 Houston, Texas, United States, 77008 Houston, Texas, United States, 77030 Irving, Texas, United States, 75062 San Antonio, Texas, United States, 78229 United States, Washington Richland, Washington, United States, 99352 Puerto Rico Caguas, Puerto Rico, 00725 Collapse <<
NCT01267188	Tardive Dyskinesia	Phase 2	Completed	-	Canada, Ontario ... more >> Toronto, Ontario, Canada, M5T 1R8 Collapse <<
NCT01688037	Tardive Dyskinesia	Phase 2	Completed	-	-
NCT01733121	-	-	Completed	-	-
NCT01393600	-	-	Completed	-	-
NCT01688037	-	-	Completed	-	-
NCT02274558	Tardive Dyskinesia	Phase 3	Completed	-	-
NCT02405091	Tardive Dyskinesia	Phase 3	Completed	-	-
NCT02274558	-	-	Completed	-	-
NCT01910480	Effect of Ketoconazole on the ... more >>PK of NBI-98854 in Healthy Subjects Collapse <<	Phase 1	Completed	-	United States, Arizona ... more >> Celerion Tempe, Arizona, United States, 85283 Collapse <<
NCT01916993	Safety, Tolerability, and PK o... more >>f NBI-98854 in Hepatically Impaired Subjects Collapse <<	Phase 1	Completed	-	United States, Colorado ... more >> DaVita Clinical Research Lakewood, Colorado, United States, 80228 United States, Florida Orlando Clinical Research Center Orlando, Florida, United States, 32809 United States, Minnesota Davita Clinical Research Minneapolis, Minnesota, United States, 55404 Collapse <<
NCT03325010	Tourette Syndrome	Phase 2	Recruiting	December 2018	-
NCT02405091	-	-	Completed	-	-
NCT03732534	Tourette Syndrome	Phase 2	Enrolling by invitation	August 2020	United States, California ... more >> Neurocrine Clinical Site Anaheim, California, United States, 92805 Neurocrine Clinical Site San Diego, California, United States, 92108 United States, Florida Neurocrine Clinical Site Hialeah, Florida, United States, 33013 United States, Illinois Neurocrine Clinical Site Chicago, Illinois, United States, 60634 Neurocrine Clinical Site Naperville, Illinois, United States, 60563 United States, Nebraska Neurocrine Clinical Site Lincoln, Nebraska, United States, 68526 United States, Texas Neurocrine Clinical Site Houston, Texas, United States, 77058 Collapse <<
NCT03444038	Tourette Syndrome	Phase 2	Enrolling by invitation	June 2019	-
NCT03530293	Tourette Syndrome	Phase 2	Recruiting	February 2020	-
NCT03698331	Tardive Dyskinesia (TD)	Phase 4	Recruiting	April 2019	United States, California ... more >> Neurocrine Clinical Site Recruiting Anaheim, California, United States, 92804 Neurocrine Clinical Site Recruiting Glendale, California, United States, 91206 Neurocrine Clinical Site Recruiting Norwalk, California, United States, 90650 Neurocrine Clinical Site Recruiting Oceanside, California, United States, 92054 Neurocrine Clinical Site Recruiting San Bernardino, California, United States, 92108 United States, Florida Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33012 Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33013 Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33018 United States, Hawaii Neurocrine Clinical Site Recruiting Honolulu, Hawaii, United States, 96817 United States, Michigan Neurocrine Clinical Site Recruiting Ann Arbor, Michigan, United States, 48105 United States, Ohio Neurocrine Clinical Site Recruiting Beechwood, Ohio, United States, 44122 United States, Oklahoma Neurocrine Clinical Site Recruiting Oklahoma City, Oklahoma, United States, 73112 United States, Pennsylvania Neurocrine Clinical Site Recruiting Scranton, Pennsylvania, United States, 18503 United States, Texas Neurocrine Clinical Site Recruiting DeSoto, Texas, United States, 75115 Neurocrine Clinical Site Recruiting Irving, Texas, United States, 75062 Puerto Rico Neurocrine Clinical Site Recruiting San Juan, Puerto Rico, 00926 Collapse <<
NCT02736955	Tardive Dyskinesia	Phase 3	Unknown	-	-

Valbenazine Catalog No. CSN13715

靶点选择性

请登录您的专属账户

确认信息